Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease as well as preparation method and application of traditional Chinese medicine composition

Abstract

The invention discloses a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition comprises the following components in parts by weight: 140-200 parts of astragalus membranaceus, 60-120 parts of rehmannia, 40-80 parts of fructus psoraleae, 15-50 parts of walnut kernel, 40-80 parts of aster, 140-200 parts of codonopsis pilosula, 50-85 parts of radix paeoniae rubra, 15-45 parts of schisandra chinensis and 50-80 parts of white mulberry root-bark. The traditional Chinese medicine composition has a good treatment effect on the chronic obstructive pulmonary disease, and meanwhile, the composition is small in side effect and small in harm to the human body.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, a preparation method thereof, and an application thereof. Background Art

[0002] Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, characterized by persistent respiratory symptoms and airflow limitation. According to the conditions of cough, expectoration, chest tightness, and wheezing, it is divided into the acute exacerbation period and the stable period. At present, the treatment of the acute exacerbation period at home and abroad is relatively mature, including drug treatments such as bronchodilators, glucocorticoids, methylxanthines, and antioxidants, as well as non-drug treatment measures such as lung volume reduction surgery and bronchoscopic lung volume reduction surgery. The above methods can effectively relieve symptoms such as cough, expectoration, and dyspnea in the acute period, but there are still disadvantages such as many drug side effects and high prices, and they have poor effects on improving accompanying symptoms such as fatigue, shortness of breath, poor appetite, and soreness and weakness of the waist and knees, and cannot delay the disease progression and improve the long-term prognosis. Finding appropriate means to intervene in the management of the stable period of chronic obstructive pulmonary disease has become a hot and key point of exploration. Summary of the Invention

[0003] In view of the above deficiencies in the prior art, the present invention provides a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, a preparation method thereof, and an application thereof. The traditional Chinese medicine composition has a good therapeutic effect on chronic obstructive pulmonary disease. At the same time, the composition has small side effects and less harm to the human body.

[0004] To achieve the above object, the technical solution adopted by the present invention to solve its technical problems is:

[0005] A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, comprising the following components in parts by weight: 140 - 200 parts of Astragalus membranaceus, 60 - 120 parts of Rehmannia glutinosa, 40 - 80 parts of Psoralea corylifolia, 15 - 50 parts of walnut kernels, 40 - 80 parts of Aster tataricus, 140 - 200 parts of Codonopsis pilosula, 50 - 85 parts of Paeonia lactiflora, 15 - 45 parts of Schisandra chinensis, and 50 - 80 parts of Morus alba root bark.

[0006] Further, it comprises the following components in parts by weight: 170 - 190 parts of Astragalus membranaceus, 80 - 100 parts of Rehmannia glutinosa, 55 - 70 parts of Psoralea corylifolia, 30 - 45 parts of walnut kernels, 55 - 70 parts of Aster tataricus, 170 - 190 parts of Codonopsis pilosula, 65 - 80 parts of Paeonia lactiflora, 25 - 35 parts of Schisandra chinensis, and 65 - 80 parts of Morus alba root bark.

[0007] Furthermore, it includes the following components in parts by weight: 170 parts of Astragalus membranaceus, 80 parts of Rehmannia glutinosa, 70 parts of Psoralea corylifolia, 30 parts of walnut kernels, 70 parts of Aster tataricus, 190 parts of Codonopsis pilosula, 80 parts of Paeonia lactiflora, 25 parts of Schisandra chinensis, and 65 parts of Morus alba root bark.

[0008] Furthermore, it includes the following components in parts by weight: 190 parts of Astragalus membranaceus, 100 parts of Rehmannia glutinosa, 55 parts of Psoralea corylifolia, 45 parts of walnut kernels, 55 parts of Aster tataricus, 170 parts of Codonopsis pilosula, 65 parts of Paeonia lactiflora, 35 parts of Schisandra chinensis, and 80 parts of Morus alba root bark.

[0009] Furthermore, it includes the following components in parts by weight: 180 parts of Astragalus membranaceus, 90 parts of Rehmannia glutinosa, 60 parts of Psoralea corylifolia, 35 parts of walnut kernels, 64 parts of Aster tataricus, 185 parts of Codonopsis pilosula, 75 parts of Paeonia lactiflora, 30 parts of Schisandra chinensis, and 75 parts of Morus alba root bark.

[0010] Furthermore, the Astragalus membranaceus is prepared Radix Astragali Praeparata, the Rehmannia glutinosa is prepared Rehmanniae Radix Praeparata, the Psoralea corylifolia is prepared Fructus Psoraleae Praeparata cum Sale, the Aster tataricus is prepared Flos Asteris Praeparata cum Melle, the Codonopsis pilosula is prepared Radix Codonopsis Praeparata cum Semine Oryzae, the Schisandra chinensis is prepared Fructus Schisandrae Chinensis Praeparata cum Vinegar, and the Morus alba root bark is prepared Cortex Mori Praeparata cum Melle.

[0011] The preparation method of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease is: crushing and mixing the raw materials; or making the extracts obtained by mixing or separately extracting the raw materials; or making the active ingredients obtained by further refining and purifying the extracts; or adding pharmaceutically acceptable excipients to the extracts / active ingredients.

[0012] Furthermore, the dosage form prepared is one of pills, granules, capsules, powders, mixtures or oral liquids.

[0013] Furthermore, the specific preparation method is: taking the above nine herbs, decocting with water, filtering the decoction liquid, combining the filtrates, concentrating under reduced pressure to a clear paste with a relative density of 1.15 - 1.25, and granulating with pharmaceutically acceptable excipients to obtain.

[0014] The application of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in the preparation of drugs for treating chronic obstructive pulmonary disease.

[0015] The beneficial effects produced by the present invention are:

[0016] In the present invention, Astragalus membranaceus is sweet, slightly warm, and belongs to the lung meridian, with the effects of invigorating qi and ascending yang, benefiting the defensive qi and strengthening the superficies, promoting diuresis and alleviating edema, and promoting granulation and generating muscle. It can both greatly invigorate the qi of the spleen and lung and stop sweating by strengthening the superficies, and is used as the monarch drug;

[0017] Psoralea corylifolia L. is pungent, bitter, and warm in nature, and enters the kidney and spleen meridians. It has the effects of tonifying the kidney and assisting yang, consolidating essence and reducing urination, warming the spleen and stopping diarrhea, and taking in qi to relieve asthma. Its pungency, bitterness, and great warmth are used to tonify the fire of the gate of vitality to warm and nourish the spleen earth; Rehmannia glutinosa Libosch. is sweet and warm, and has the effects of nourishing yin and blood, and replenishing essence and marrow. It is used to replenish the kidney and fill the essence; Juglans regia L. has the effects of tonifying the kidney and consolidating essence, warming the lungs and relieving asthma. It is used to play the roles of tonifying the kidney, astringing the lungs, and relieving asthma. The combination of these three herbs replenishes the kidney and fills the essence, promotes the generation of metal from water, tonifies deficiency and relieves asthma, treats both the lung and the kidney, and they together serve as ministerial herbs;

[0018] Codonopsis pilosula (Franch.) Nannf. is sweet and neutral, and enters the spleen and lung meridians. It has the effects of replenishing qi, promoting the production of body fluid, and nourishing blood, playing the roles of strengthening the spleen and replenishing qi, promoting the transportation and transformation of the spleen and stomach, generating metal from earth, and cutting off the source of phlegm production, and assisting all the herbs to circulate throughout the body; Schisandra chinensis (Turcz.) Baill. is sour, sweet, and warm, and enters the lung, heart, and kidney meridians. It has the effects of astringing the lungs and nourishing the kidneys, promoting the production of body fluid and astringing sweating, astringing essence and stopping diarrhea, and calming the mind and tranquilizing the spirit. Its sour and warm nature is especially good at astringing the lungs and stopping sweating, and promoting the production of body fluid and quenching thirst; Paeonia lactiflora Pall. has the effects of regulating nutrition and nourishing blood, cooling blood and promoting blood circulation; Morus alba L. mainly enters the lung meridian and has the effects of clearing away heat and purging the lung, relieving asthma and cough; Aster tataricus L. f. var. heterophyllus Maxim. is pungent, sweet, and bitter, warm in nature, and enters the lung meridian. It has the effects of moistening the lungs and resolving phlegm, and relieving cough in the lungs; Morus alba L. processed with honey is sweet and cold, and enters the lung meridian. It has the effects of purging the lung and relieving asthma, and promoting diuresis and reducing swelling. It is a mild herb to prevent excessive cold from damaging the healthy qi;

[0019] Codonopsis pilosula (Franch.) Nannf. and Astragalus membranaceus (Fisch.) Bge. nourish the stomach and benefit the lungs, enabling the metal to be clear and the qi to be purified, so that asthma and cough can be alleviated. Codonopsis pilosula (Franch.) Nannf. tonifies, Morus alba L. clears, and Schisandra chinensis (Turcz.) Baill. astringes. The combination of these three herbs together exerts the effects of replenishing qi and nourishing yin, promoting the production of body fluid and quenching thirst, astringing yin and stopping sweating, enabling sweating to stop and yin to be preserved, qi to be restored and body fluid to be generated. For those with phlegm retention, the monarch and ministerial herbs are purely warm-tonifying herbs. It is necessary to prevent the warm herbs from damaging body fluid. Therefore, Schisandra chinensis (Turcz.) Baill. with its sour taste is used to astringe qi, and Paeonia lactiflora Pall. is used to regulate nutrition and nourish blood, cool blood and promote blood circulation for the purpose of assisting and controlling; Codonopsis pilosula (Franch.) Nannf. is sweet and warm, replenishing qi and promoting the production of body fluid to tonify the lungs. When the lung qi is strong, the qi of the four zang-organs will all be strong, and it also assists the monarch herb Astragalus membranaceus (Fisch.) Bge. to strengthen the power of replenishing qi and consolidating the exterior. The combination of Codonopsis pilosula (Franch.) Nannf. and Astragalus membranaceus (Fisch.) Bge. makes the qi strong and the exterior solid, so that sweating does not leak out and pathogenic factors are not easily invaded. These are used as assistant herbs. Morus alba L. guides the herbs to enter the lung as the envoy herb. The whole formula altogether achieves the effects of tonifying the lung and kidney, relieving cough and asthma. Detailed implementation mode

[0020] In order to make the purpose, technical solutions and advantages of the present invention clearer, the following further elaborates on the present invention in combination with embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention, that is, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments.

[0021] Therefore, the following detailed description of the provided embodiments of the present invention is not intended to limit the scope of the claimed present invention, but only represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative efforts belong to the scope of protection of the present invention.

[0022] It should be noted that relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship or order between these entities or operations. Moreover, the terms "comprising", "including" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device comprising a series of elements not only includes those elements, but also includes other elements not expressly listed, or also includes elements inherent in such process, method, article or device. Without further limitation, an element defined by the statement "comprising one..." does not exclude the existence of additional identical elements in the process, method, article or device comprising the element.

[0023] The features and performance of the present invention will be further described in detail below in conjunction with the embodiments.

[0024] Example 1

[0025] A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease is made from the following components in parts by weight: 200 g of Astragalus membranaceus, 120 g of Rehmannia glutinosa, 40 g of Psoralea corylifolia, 50 g of Juglans regia, 40 g of Aster tataricus, 140 g of Codonopsis pilosula, 50 g of Paeonia lactiflora, 45 g of Schisandra chinensis, and 80 g of Morus alba root bark.

[0026] The preparation method of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease comprises the following steps: The above nine flavors are decocted in water three times, each time for 1 hour. For the first time, 11 times the amount of water is added, and for the last two times, 10 times the amount of water is added respectively. The decoction is filtered, and the filtrates are combined and concentrated under reduced pressure to a clear paste with a relative density of 1.15 (60 °C), and granulated in one step with an appropriate amount of dextrin to make 1000 g, thus obtaining.

[0027] Example 2

[0028] A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease is made from the following components in parts by weight: 140 g of Astragalus membranaceus, 60 g of Rehmannia glutinosa, 80 g of Psoralea corylifolia, 15 g of Juglans regia, 80 g of Aster tataricus, 200 g of Codonopsis pilosula, 85 g of Paeonia lactiflora, 15 g of Schisandra chinensis, and 50 g of Morus alba root bark.

[0029] The preparation method of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease comprises the following steps: The above nine flavors are decocted in water three times, each time for 1 hour. For the first time, 11 times the amount of water is added, and for the last two times, 10 times the amount of water is added respectively. The decoction is filtered, and the filtrates are combined and concentrated under reduced pressure to a clear paste with a relative density of 1.25 (60 °C), and granulated in one step with an appropriate amount of dextrin to make 1000 g, thus obtaining.

[0030] Example 3

[0031] A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, which is made from the following components in parts by weight: 170 g of Astragalus membranaceus, 80 g of Rehmannia glutinosa, 70 g of Psoralea corylifolia, 30 g of walnut kernels, 70 g of Aster tataricus, 190 g of Codonopsis pilosula, 80 g of Paeonia lactiflora, 25 g of Schisandra chinensis, and 65 g of Morus alba root bark.

[0032] The preparation method of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease includes the following steps: The above nine herbs are decocted with water three times, each time for 1 hour. For the first time, 11 times the amount of water is added, and for the latter two times, 10 times the amount of water is added respectively. The decoction is filtered, and the filtrates are combined and concentrated under reduced pressure to obtain a clear paste with a relative density of 1.15 (60 °C), and then granulated in one step with an appropriate amount of dextrin to make 1000 g, thus obtaining the product.

[0033] Example 4

[0034] A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, which is made from the following components in parts by weight: 190 g of Astragalus membranaceus, 100 g of Rehmannia glutinosa, 55 g of Psoralea corylifolia, 45 g of walnut kernels, 55 g of Aster tataricus, 170 g of Codonopsis pilosula, 65 g of Paeonia lactiflora, 35 g of Schisandra chinensis, and 80 g of Morus alba root bark.

[0035] The preparation method of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease includes the following steps: The above nine herbs are decocted with water three times, each time for 1 hour. For the first time, 11 times the amount of water is added, and for the latter two times, 10 times the amount of water is added respectively. The decoction is filtered, and the filtrates are combined and concentrated under reduced pressure to obtain a clear paste with a relative density of 1.20 (60 °C), and then granulated in one step with an appropriate amount of dextrin to make 1000 g, thus obtaining the product.

[0036] Example 5

[0037] A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, which is made from the following components in parts by weight: 180 g of Astragalus membranaceus, 90 g of Rehmannia glutinosa, 60 g of Psoralea corylifolia, 35 g of walnut kernels, 64 g of Aster tataricus, 185 g of Codonopsis pilosula, 75 g of Paeonia lactiflora, 30 g of Schisandra chinensis, and 75 g of Morus alba root bark.

[0038] The preparation method of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease includes the following steps: The above nine herbs are decocted with water three times, each time for 1 hour. For the first time, 11 times the amount of water is added, and for the latter two times, 10 times the amount of water is added respectively. The decoction is filtered, and the filtrates are combined and concentrated under reduced pressure to obtain a clear paste with a relative density of 1.20 (60 °C), and then granulated in one step with an appropriate amount of dextrin to make 1000 g, thus obtaining the product.

[0039] Comparative Example 1

[0040] A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease is made up of the following components in parts by weight: 180 g of astragalus membranaceus, 60 g of psoralea corylifolia, 35 g of walnut kernels, 64 g of aster tataricus, 185 g of codonopsis pilosula, 75 g of red peony root, 30 g of schizandra chinensis, and 75 g of mulberry bark.

[0041] The preparation method of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease includes the following steps: The above eight herbs are decocted with water three times, each time for 1 hour. For the first time, 11 times the amount of water is added, and for the latter two times, 10 times the amount of water is added respectively. The decoction is filtered, and the filtrates are combined and concentrated under reduced pressure to a clear paste with a relative density of 1.20 (60 °C), and granulated in one step with an appropriate amount of dextrin to make 1000 g, thus obtaining the product.

[0042] Comparative Example 2

[0043] A traditional Chinese medicine composition for treating chronic obstructive pulmonary disease is made up of the following components in parts by weight: 180 g of astragalus membranaceus, 90 g of rehmannia glutinosa, 64 g of aster tataricus, 185 g of codonopsis pilosula, 75 g of red peony root, 30 g of schizandra chinensis, and 75 g of mulberry bark.

[0044] The preparation method of the above traditional Chinese medicine composition for treating chronic obstructive pulmonary disease includes the following steps: The above seven herbs are decocted with water three times, each time for 1 hour. For the first time, 11 times the amount of water is added, and for the latter two times, 10 times the amount of water is added respectively. The decoction is filtered, and the filtrates are combined and concentrated under reduced pressure to a clear paste with a relative density of 1.20 (60 °C), and granulated in one step with an appropriate amount of dextrin to make 1000 g, thus obtaining the product.

[0045] Test Example

[0046] 1. General information

[0047] 60 patients who came to the hospital for treatment and were diagnosed with chronic obstructive pulmonary disease were randomly selected, including 30 males and 30 females, with an age range of 40 - 70 years.

[0048] 2. Disease diagnosis criteria

[0049] Symptom manifestations: There is chronic cough, with obvious morning cough, nocturnal paroxysmal cough or expectoration; the sputum is white mucus or serous frothy sputum, occasionally with blood streaks, and more sputum is expectorated in the early morning; there is shortness of breath or dyspnea, which appears during early exertion and progresses to shortness of breath even during daily activities or at rest as the disease progresses; some patients have wheezing and chest tightness; in severe cases, systemic symptoms such as weight loss and loss of appetite appear.

[0050] Chest imaging examination: Chest X-ray or CT examination shows lesions in the lungs such as inflammation, fibrosis, emphysema, etc., such as thickening and disorder of lung markings and pulmonary broncho-vascular bundles, and some patients have manifestations related to cor pulmonale.

[0051] Exclude other diseases: Exclude other diseases that may cause similar symptoms, such as bronchial asthma, congestive heart failure, bronchiectasis, tuberculosis, bronchiolitis obliterans, diffuse panbronchiolitis, etc.

[0052] 3. Inclusion criteria

[0053] (1) Meet the above diagnostic criteria for chronic obstructive pulmonary disease;

[0054] (2) Be aged 40 years or older;

[0055] (3) The patient voluntarily signs an informed consent form and is willing to cooperate with various examinations and treatments during the study;

[0056] (4) Be able to be followed up regularly to ensure the integrity and traceability of the data.

[0057] 4. Case exclusion criteria

[0058] (1) Have other serious pulmonary diseases that affect lung function or may interfere with the judgment of the results of this study, such as interstitial lung disease, etc.;

[0059] (2) Have experienced major cardiovascular events such as acute myocardial infarction and cerebrovascular accident in the past 3 months;

[0060] (3) Have systemic diseases such as severe liver and kidney insufficiency, malignant tumor, hematological diseases, and low immune function;

[0061] (4) Be a female patient in the pregnancy or lactation period;

[0062] (5) Have a history of allergy to the drugs used in this study;

[0063] (6) Have mental illness or cognitive impairment and be unable to cooperate with the study.

[0064] 5. Treatment methods

[0065] Taking the traditional Chinese medicine compositions in Example 5, Comparative Example 1, and Comparative Example 2 as an example, the diagnosed patients were randomly divided into 3 groups, with 20 people in each group. Each group of patients was given the drugs in Example 5, Comparative Example 1, and Comparative Example 2 orally, 2 times a day, 20 g each time, for 15 consecutive days. After the treatment, the patient conditions were statistically analyzed.

[0066] 6. Efficacy evaluation criteria

[0067] Clinical control: Symptoms such as cough, expectoration, and dyspnea basically disappear, the percentage of FEV 1 in the predicted value increases by ≥ 30%, and FEV 1 / FVC ≥ 70%;

[0068] Effective: Symptoms are significantly alleviated, and the percentage of FEV in pulmonary function examination 1 increases by 15 - 30% of the predicted value;

[0069] Effective: Symptoms are somewhat improved, and the percentage of FEV in pulmonary function examination 1 increases by < 15% of the predicted value;

[0070] Ineffective: Symptoms show no improvement or get worse, and there is no obvious change or deterioration in pulmonary function examination.

[0071] Effective rate = (number of clinically controlled cases + effective cases + markedly effective cases) / total number of cases * 100%

[0072] 7. Efficacy statistics

[0073] The specific test results are shown in Table 1.

[0074] Table 1: Test results

[0075]

[0076] As shown by the results in the above table, the drug in Example 5 has a good therapeutic effect on chronic obstructive pulmonary disease, with a markedly effective rate as high as 95%. After adjusting the composition of the composition in Comparative Example 1 and Comparative Example 2, the therapeutic effect of the drug becomes worse. It can be known that there is an interaction relationship between the various medicinal materials in the composition of the present application, which improves the overall therapeutic effect of the composition.

[0077] Typical cases

[0078] Case 1: Sun XX, female, 62 years old, came to the hospital for treatment in January 2020. She reported that she had cough and expectoration 1 year ago. The sputum was white and foamy, accompanied by shortness of breath, chest tightness, and decreased physical strength. The effect was not obvious after seeking medical treatment and taking medicine. So she came to our hospital for treatment. The traditional Chinese medicine in Example 5 was prescribed for her. After taking it continuously for 20 days, she came to the hospital for a follow-up visit. The patient reported that the cough symptom was alleviated, the expectoration was reduced, and the symptoms of shortness of breath and chest tightness were both alleviated. The medicine was continued to be prescribed for her until the condition recovered.

[0079] Case 2: Wang XX, female, 47 years old, came to the hospital for treatment in October 2021. She reported that she had cough and expectoration half a year ago. The sputum was white and foamy, accompanied by chest tightness, shortness of breath, fatigue, and a feeling of stuffiness and distension at night. The symptom alleviation was not obvious after seeking medical treatment and taking medicine. So she came to our hospital for treatment. The traditional Chinese medicine in Example 5 was prescribed for her. After taking it continuously for 15 days, she came for a follow-up visit. The patient reported that the cough was alleviated, the expectoration was reduced, and the symptoms of chest tightness, shortness of breath, fatigue, and stuffiness and distension were all alleviated. The patient's mental state and energy were significantly improved. The medicine was continued to be prescribed for her until the condition recovered.

[0080] Case 3: Wang XX, male, 44 years old, came to the hospital for treatment in April 2022. He reported having a smoking history. Cough and expectoration occurred 3 years ago, with white or slightly yellowish sputum in a foamy shape. In the past year, he had symptoms of chest tightness, shortness of breath, and physical fatigue, with the chest tightness worsening at night and difficulty breathing. After seeking medical advice and taking medicine, the symptoms did not change significantly. So he came to our hospital for treatment, and the medicine in Example 5 was prescribed for him. After continuously taking the medicine for 25 days, he came to the hospital for a follow-up visit. He reported that the symptoms of chest tightness, shortness of breath, difficulty breathing, physical fatigue, and cough had all improved to some extent, and his spirit had improved. The medicine was prescribed for him again. After continuously taking the medicine for 20 days, he reported a significant improvement in his condition during the follow-up visit.

[0081] Case 4: Zhao XX, female, 71 years old, came to the hospital for treatment in September 2023. The patient reported that cough and expectoration occurred 5 years ago, with white or slightly yellowish sputum in a foamy shape. In the past 2 years, she had symptoms of chest tightness, shortness of breath, and fatigue, and the feeling of stuffiness at night increased. After seeking medical advice and taking medicine, the symptoms did not improve significantly. So she came to our hospital for treatment, and the medicine in Example 5 was prescribed for her. After continuously taking the medicine for 20 days, she came for a follow-up visit and reported that the symptoms of chest tightness, shortness of breath, fatigue, and cough had all improved. The medicine was prescribed for her again. After taking the medicine for 20 days, she reported during the follow-up visit that she had basically returned to a normal living state.

[0082] Case 5: Wang XX, male, 78 years old, came to the hospital for treatment in May 2024. The patient reported having a 40-year smoking history. Cough and expectoration of thin white sputum in a foamy shape occurred 6 years ago. In the past 2 years, the cough and expectoration had worsened, and were accompanied by symptoms such as chest tightness and wheezing. After seeking medical advice and taking medicine, the symptoms did not change significantly. So he came to our hospital for treatment, and the medicine in Example 5 was prescribed for him. After continuously taking the medicine for 23 days, he came to the hospital for a follow-up visit and reported that the symptoms of chest tightness and wheezing had been relieved. After continuously taking the medicine for 30 days, he reported during the follow-up visit that the chest tightness and wheezing had disappeared, and the cough and expectoration symptoms had alleviated.

Claims

1. A Chinese medicine composition for treating chronic obstructive pulmonary disease, characterized in that: The invention comprises the following components in parts by weight: 140-200 parts of astragalus, 60-120 parts of rehmannia, 40-80 parts of psoralea corylifolia, 15-50 parts of walnut kernel, 40-80 parts of aster, 140-200 parts of codonopsis pilosula, 50-85 parts of red peony root, 15-45 parts of schisandra chinensis and 50-80 parts of mulberry bark.

2. The Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 1, characterized in that: The invention comprises the following components in parts by weight: 170-190 parts of astragalus, 80-100 parts of rehmannia, 55-70 parts of psoralea corylifolia, 30-45 parts of walnut kernel, 55-70 parts of aster, 170-190 parts of codonopsis pilosula, 65-80 parts of red peony root, 25-35 parts of schisandra chinensis and 65-80 parts of mulberry bark.

3. The Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 1 or 2, characterized in that: The invention comprises the following components in parts by weight: 170 parts of astragalus, 80 parts of rehmannia, 70 parts of psoralea corylifolia, 30 parts of walnut kernel, 70 parts of aster, 190 parts of codonopsis pilosula, 80 parts of red peony root, 25 parts of schisandra chinensis and 65 parts of white mulberry bark.

4. The Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 1 or 2, characterized in that: The invention comprises the following components in parts by weight: 190 parts of astragalus, 100 parts of rehmannia, 55 parts of psoralea corylifolia, 45 parts of walnut kernel, 55 parts of aster, 170 parts of codonopsis pilosula, 65 parts of red peony root, 35 parts of schisandra chinensis and 80 parts of white mulberry bark.

5. The Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 1 or 2, characterized in that: The invention comprises the following components in parts by weight: 180 parts of astragalus, 90 parts of rehmannia, 60 parts of psoralea corylifolia, 35 parts of walnut kernel, 64 parts of aster, 185 parts of codonopsis pilosula, 75 parts of red peony root, 30 parts of schisandra chinensis and 75 parts of white mulberry bark.

6. The Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 1, characterized in that: The astragalus is roasted astragalus, the rehmannia is cooked rehmannia, the psoralea is salt psoralea, the aster is honey aster, the codonopsis is rice-fried codonopsis, the schisandra is vinegar schisandra, and the white mulberry bark is honey mulberry bark.

7. The method for preparing the Chinese medicine composition for treating chronic obstructive pulmonary disease according to any one of claims 1 to 6, characterized in that: It includes the steps of crushing and mixing the raw materials; or the extract obtained by mixing or extracting the raw materials separately; or the active ingredient obtained by further refining and purifying the extract; or the extract / active ingredient is added with pharmaceutically acceptable excipients.

8. The method for preparing the Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 7, characterized in that: The prepared dosage form is one of pills, granules, capsules, powders, mixtures or oral liquids.

9. The method for preparing the Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 8, characterized in that: The specific preparation method is: add water to the above nine ingredients and boil them, filter the decoction, combine the filtrate, and concentrate under reduced pressure to a clear paste with a relative density of 1.15-1.25, and granulate with pharmaceutically acceptable excipients to obtain the product.

10. Use of the Chinese medicine composition for treating chronic obstructive pulmonary disease according to any one of claims 1 to 6 in the preparation of a medicament for treating chronic obstructive pulmonary disease.

Images